Dividend Watch: Johnson & Johnson (NYSE:JNJ)

In all, J&J reported a profit of $3.36 billion, or $1.20 a share, down from $4.75 billion, or $1.66 a share, a year earlier.

Johnson & Johnson (NYSE:JNJ) rose 0.65% or 0.62 points on Monday and made its way into the gainers of the day.

The company increased its adjusted earnings guidance for full-year 2015 to $6.15 – $6.20 per share.

Its stock is down 8% year-to-date., and 5% over the past 12 months. Remicade’s sales in the recent quarter i.e. 3QFY15 are expected to stand at $1.698 billion, which corresponds to a decline of 4.71% YoY over its sales of $1.78 billion in 3QFY14. The firm had revenue of $17.10 billion for the quarter, compared to analyst estimates of $17.47 billion. On average, equities analysts anticipate that Johnson & Johnson will post $6.17 earnings per share for the current fiscal year. However, the stock price could fluctuate by $ 4.8 from the estimate as it is suggested by the standard deviation reading. Johnson & Johnson has a 12-month low of $81.79 and a 12-month high of $109.49.

Shares in the company, up 0.7% this year, were flat premarket.

Earnings of $1.49 a share, excluding one-time items, beat by 4 cents the average of 18 analysts’ estimates compiled by Bloomberg. The Company is engaged in the research and development, fabrication and sale of a range of products in the healthcare field. The Company also provides therapeutics for viral infections with the compound AL-8176, an orally administered antiviral therapy now in Phase 2 studies for the treatment of infants with respiratory syncytial virus (RSV). The Companys primary focus has been on products related to human health and well-being. The Organization has more than 265 managing companies conducting business all over the world. The Organization ‘s subsidiaries manage 134 production facilities occupying about 21.5 million square feet of floor space.